WHAT IS CLAIMED IS:

1. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for initiation and titration of a GLP-1 agonist drug regimen for the patient according to the plurality of user-generated inputs;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1c data for the patient;

outputting, with a conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication initiation prompt for the GLP-1 agonist drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a response to the medication initiation prompt;

processing, with the at least one server, the first set of blood sugar or hemoglobin A1c data and the first voice input according to the clinical algorithm; and

outputting, with the conversational agent, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a first dosage instruction for the GLP-1 agonist drug regimen for the patient according to the clinical algorithm.;

wherein the first dosage instruction comprises a dose of the GLP-1 agonist drug to be administered to the patient by the patient.

2. The method according to claim **1** further comprising establishing a data transfer interface between a continuous glucose monitor device or a glucometer for the patient and the at least one server.

3. The method according to any one of claims **1-2** wherein the first set of blood sugar or hemoglobin a1c data for the patient comprises blood sugar or hemoglobin a1c data collected via the continuous glucose monitor device or glucometer.

4. The method according to any one of claims **1-3** further comprising:

outputting, with the conversational agent, a third generative voice prompt according to the conversational AI model, wherein the third generative voice prompt comprises a medication log prompt for the GLP-1 agonist drug regimen;

receiving, with the conversational agent, a second voice input from the patient in response to the third generative voice prompt, wherein the second voice input comprises medication log data for the patient; and

recording, with the at least one server, the medication log data for the patient according to the second voice input.

5. The method according to any one of claims **1-4** further comprising:

receiving, with the at least one server, a second set of blood sugar or hemoglobin a1c data for the patient; and

analyzing, with the at least one server, the second set of blood sugar or hemoglobin a1c data and the medication log data for the patient according to the clinical algorithm.

6. The method according to any one of claims **1-5** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the conversational AI model, wherein the fourth generative voice prompt comprises a second dosage instruction for the GLP-1 agonist drug regimen for the patient according to the clinical algorithm; and

administering, by the patient, a second dose of the GLP-1 agonist drug to the patient in accordance with the second dosage instruction.

7. The method according to any one of claims **1-6** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the conversational AI model, wherein the fourth generative voice prompt comprises a check-in prompt for the patient;

receiving, with the conversational agent, a third voice input from the patient in response to the fourth generative voice prompt, wherein the third voice input comprises a response to the check-in prompt; and

recording, with the at least one server, response data for the patient according to the third voice input.

8. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for initiation and titration of a biguanide drug regimen for the patient according to the plurality of user-generated inputs;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1c data for the patient;

outputting, with a conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication initiation prompt for the biguanide drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a response to the medication initiation prompt;

processing, with the at least one server, the first set of blood sugar or hemoglobin A1c data and the first voice input according to the clinical algorithm; and

outputting, with the conversational agent, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a first dosage instruction for the biguanide drug regimen for the patient according to the clinical algorithm.; and

wherein the first dosage instruction comprises a dose of the biguanide drug to be administered to the patient by the patient.

9. The method according to any one of claims **8** further comprising:

outputting, with the conversational agent, a third generative voice prompt according to the conversational AI model, wherein the third generative voice prompt comprises a medication log prompt for the biguanide drug regimen;

receiving, with the conversational agent, a second voice input from the patient in response to the third generative voice prompt, wherein the second voice input comprises medication log data for the patient; and

recording, with the at least one server, the medication log data for the patient according to the second voice input.

10. The method according to any one of claims **8-9** further comprising analyzing, with the at least one server, the medication log data for the patient according to the clinical algorithm to determine a measure of patient adherence to the biguanide drug regimen.

11. The method according to any one of claims **8-10** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the conversational AI model, wherein the fourth generative voice prompt comprises a second medication dosage instruction for the biguanide drug regimen for the patient according to the clinical algorithm; and

wherein the second medication dosage instruction comprises a second dose of the biguanide drug to be administered to the patient by the patient.

12. The method according to any one of claims **8-11** wherein the second dose of the biguanide drug is different from the first dose of the biguanide drug according to the biguanide drug regimen.

13. The method according to any one of claims **8-12** further comprising receiving, with the at least one server, a first set of electronic medical record data for the patient, wherein the first set of electronic medical record data comprises laboratory test data.

14. The method according to any one of claims **8-13** further comprising updating, with the at least one server, the clinical algorithm for initiation and titration of the biguanide drug regimen for the patient according to the first set of electronic medical record data for the patient.

15. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for initiation and titration of a SGLT-2 inhibitor drug regimen for the patient according to the plurality of user-generated inputs;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1c data for the patient;

outputting, with a conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication initiation prompt for the SGLT-2 inhibitor drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a response to the medication initiation prompt;

processing, with the at least one server, the first set of blood sugar or hemoglobin A1c data and the first voice input according to the clinical algorithm; and

outputting, with the conversational agent, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a first dosage instruction for the SGLT-2 inhibitor drug regimen for the patient according to the clinical algorithm; and

wherein the first dosage instruction comprises a dose of the SGLT-2 inhibitor drug to be administered to the patient by the patient.

16. The method according to claim **15** further comprising:

outputting, with the conversational agent, a third generative voice prompt according to the conversational AI model, wherein the third generative voice prompt comprises a medication log prompt for the SGLT-2 inhibitor drug regimen;

receiving, with the conversational agent, a second voice input from the patient in response to the third generative voice prompt, wherein the second voice input comprises medication log data for the patient; and

recording, with the at least one server, the medication log data for the patient according to the second voice input.

17. The method according to any one of claims **15-16** further comprising:

receiving, with the at least one server, a second set of blood sugar or hemoglobin a1c data for the patient; and

analyzing, with the at least one server, the second set of blood sugar or hemoglobin a1c data and the medication log data for the patient according to the clinical algorithm.

18. The method according to any one of claims **15-17** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the conversational AI model, wherein the fourth generative voice prompt comprises a second dosage instruction for the SGLT-2 inhibitor drug regimen for the patient according to the clinical algorithm; and

wherein the second dosage instruction comprises a second dose of the SGLT-2 inhibitor drug to be administered to the patient by the patient.

19. The method according to any one of claims **15-18** wherein the second dose of the SGLT-2 inhibitor drug is different from the first dose of the SGLT-2 inhibitor drug according to the SGLT-2 inhibitor drug regimen.

20. The method according to any one of claims **15-19** further comprising analyzing, with the at least one server, the medication log data for the patient according to the clinical algorithm to determine a measure of patient adherence to the SGLT-2 inhibitor drug regimen.

21. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for initiation and titration of an insulin regimen for the patient according to the plurality of user-generated inputs;

configuring, with the at least one server, a large language model according to the clinical algorithm;

receiving, with the at least one server, a first set of blood sugar data for the patient;

outputting, with a conversational agent, a first generative voice prompt to the patient according to the large language model, wherein the first generative voice prompt comprises a medication initiation prompt,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a response to the medication initiation prompt;

processing, with the at least one server, the first set of blood sugar data and the first voice input according to the clinical algorithm; and

outputting, with the conversational agent, a second generative voice prompt according to the large language model, wherein the second generative voice prompt comprises a first insulin dosage instruction for the patient according to the clinical algorithm; and

wherein the first insulin dosage instruction comprises a dose of insulin to be administered to the patient by the patient.

22. The method according to claim **21** further comprising establishing a data transfer interface between a continuous glucose monitor device for the patient and the at least one server.

23. The method according to any one of claims **21-22** wherein the first set of blood sugar data for the patient comprises blood sugar data collected via the continuous glucose monitor device.

24. The method according to any one of claims **21-23** further comprising:

outputting, with the conversational agent, a third generative voice prompt according to the large language model, wherein the third generative voice prompt comprises an insulin log prompt;

receiving, with the conversational agent, a second voice input from the patient in response to the third generative voice prompt, wherein the second voice input comprises insulin log data for the patient; and

recording, with the at least one server, the insulin log data for the patient according to the second voice input.

25. The method according to any one of claims **21-24** further comprising:

receiving, with the at least one server, a second set of blood sugar data for the patient; and

analyzing, with the at least one server, the second set of blood sugar data and the insulin log data for the patient according to the clinical algorithm.

26. The method according to any one of claims **21-25** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the large language model, wherein the fourth generative voice prompt comprises a second insulin dosage instruction for the patient according to the clinical algorithm; and

wherein the second insulin dosage instruction comprises a second dose of insulin to be administered to the patient by the patient.

27. The method according to any one of claims **21-26** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the large language model, wherein the fourth generative voice prompt comprises a check-in prompt for the patient;

receiving, with the conversational agent, a third voice input from the patient in response to the fourth generative voice prompt, wherein the third voice input comprises a response to the check-in prompt; and

recording, with the at least one server, response data for the patient according to the third voice input.

28. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for initiation and titration of a medication regimen for the patient according to the plurality of user-generated inputs;

configuring, with the at least one server, a large language model according to the clinical algorithm;

receiving, with the at least one server, a first set of clinical data for the patient;

outputting, with a conversational agent, a first generative voice prompt to the patient according to the large language model, wherein the first generative voice prompt comprises a medication initiation prompt,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a response to the medication initiation prompt;

processing, with the at least one server, the first set of clinical data and the first voice input according to the clinical algorithm; and

outputting, with the conversational agent, a second generative voice prompt according to the large language model, wherein the second generative voice prompt comprises a first medication dosage instruction for the patient according to the clinical algorithm; and

wherein the first medication dosage instruction comprises a first dose of metformin to be administered to the patient by the patient.

29. The method according to claim **28**, wherein the first medication dosage instruction further comprises a first dose of empagliflozin to be administered to the patient by the patient.

30. The method according to any one of claims **28-29**, wherein the first medication dosage instruction further comprises a first dose of basal insulin to be administered to the patient by the patient.

31. The method according to any one of claims **28-30**, wherein the first medication dosage instruction further comprises a first dose of prandial insulin to be administered to the patient by the patient.

32. The method according to any one of claims **28-31** further comprising:

outputting, with the conversational agent, a third generative voice prompt according to the large language model, wherein the third generative voice prompt comprises a medication log prompt;

receiving, with the conversational agent, a second voice input from the patient in response to the third generative voice prompt, wherein the second voice input comprises medication log data for the patient; and

recording, with the at least one server, the medication log data for the patient according to the second voice input.

33. The method according to any one of claims **28-32** further comprising analyzing, with the at least one server, the medication log data for the patient according to the clinical algorithm.

34. The method according to any one of claims **28-33** further comprising:

outputting, with the conversational agent, a fourth generative voice prompt according to the large language model, wherein the fourth generative voice prompt comprises a second medication dosage instruction for the patient according to the clinical algorithm; and

administering, by the patient, a second dose of metformin to the patient in accordance with the second medication dosage instruction.

35. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient,

wherein the plurality of clinical parameters comprise at least one dosage amount and at least one dosage frequency for a glucagon-like peptide 1 (GLP-1) agonist drug in a GLP-1 agonist drug regimen,

wherein the plurality of clinical parameters comprise at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for the GLP-1 agonist drug regimen for the patient according to the plurality of user-generated inputs,

wherein the clinical algorithm comprises parameters for titrating the at least one dosage amount and modifying the at least one dosage frequency for the GLP-1 agonist drug in the GLP-1 agonist drug regimen according to the at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm,

wherein the conversational AI model comprises a large language model configured to drive a plurality of generative text-to-speech outputs of a conversational agent;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1C data for the patient;

outputting, with the conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication log prompt for the GLP-1 agonist drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a first set of medication log data for the GLP-1 agonist drug for the patient;

processing, with the at least one server, the first set of medication log data for the GLP-1 agonist drug for the patient and the first set of blood sugar or hemoglobin A1C data for the patient according to the clinical algorithm;

titrating a dosage amount and/or modifying a dosage frequency of the GLP-1 agonist drug for the patient in response to processing the first set of medication log data for the GLP-1 agonist drug for the patient and the first set of blood sugar or hemoglobin A1C data according to the clinical algorithm;

configuring, with the at least one server, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a dosage instruction for the GLP-1 agonist drug regimen for the patient,

wherein the dosage instruction comprises the titrated dosage amount and/or the modified dosage frequency for the GLP-1 agonist drug according to the clinical algorithm; and

outputting, with the conversational agent, the second generative voice prompt to the patient;

wherein the dosage instruction is provided by the second generative voice prompt, the dosage instruction comprises a dose of the GLP-1 agonist drug to be administered to the patient by the patient.

36. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient,

wherein the plurality of clinical parameters comprise at least one dosage amount and at least one dosage frequency for a biguanide drug in a biguanide drug regimen,

wherein the plurality of clinical parameters comprise at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for the biguanide drug regimen for the patient according to the plurality of user-generated inputs,

wherein the clinical algorithm comprises parameters for titrating the at least one dosage amount and modifying the at least one dosage frequency for the biguanide drug in the biguanide drug regimen according to the at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm,

wherein the conversational AI model comprises a large language model configured to drive a plurality of generative text-to-speech outputs of a conversational agent;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1C data for the patient;

outputting, with the conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication log prompt for the biguanide drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a first set of medication log data for the biguanide drug for the patient;

processing, with the at least one server, the first set of medication log data for the biguanide drug for the patient and the first set of blood sugar or hemoglobin A1C data for the patient according to the clinical algorithm;

titrating a dosage amount and/or modifying a dosage frequency of the biguanide drug for the patient in response to processing the first set of medication log data for the biguanide drug for the patient and the first set of blood sugar or hemoglobin A1C data according to the clinical algorithm;

configuring, with the at least one server, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a dosage instruction for the biguanide drug regimen for the patient,

wherein the dosage instruction comprises the titrated dosage amount and/or the modified dosage frequency for the biguanide drug according to the clinical algorithm; and

outputting, with the conversational agent, the second generative voice prompt to the patient; and

wherein the dosage instruction is provided by the second generative voice prompt, the dosage instruction comprises a dose of the biguanide drug to be administered to the patient by the patient.

37. A method for management of type 2 diabetes comprising:

receiving, from a practitioner user via a first client device, a plurality of user-generated inputs comprising a plurality of clinical parameters for management of type 2 diabetes in a patient,

wherein the plurality of clinical parameters comprise at least one dosage amount and at least one dosage frequency for a sodium-glucose cotransporter-2 (SGLT-2) inhibitor drug in a SGLT-2 inhibitor drug regimen,

wherein the plurality of clinical parameters comprise at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with at least one server communicably engaged with the first client device, a clinical algorithm for the SGLT-2 inhibitor drug regimen for the patient according to the plurality of user-generated inputs,

wherein the clinical algorithm comprises parameters for titrating the at least one dosage amount and modifying the at least one dosage frequency for the SGLT-2 inhibitor drug in the SGLT-2 inhibitor drug regimen according to the at least one blood sugar or hemoglobin A1C range for the patient;

configuring, with the at least one server, a conversational AI model according to the clinical algorithm,

wherein the conversational AI model comprises a large language model configured to drive a plurality of generative text-to-speech outputs of a conversational agent;

receiving, with the at least one server, a first set of blood sugar or hemoglobin A1C data for the patient;

outputting, with the conversational agent, a first generative voice prompt to the patient according to the conversational AI model, wherein the first generative voice prompt comprises a medication log prompt for the SGLT-2 inhibitor drug regimen,

wherein the conversational agent comprises a smart speaker communicably engaged with the at least one server via a network interface;

receiving, with the conversational agent, a first voice input from the patient in response to the first generative voice prompt, wherein the first voice input comprises a first set of medication log data for the SGLT-2 inhibitor drug for the patient;

processing, with the at least one server, the first set of medication log data for the SGLT-2 inhibitor drug for the patient and the first set of blood sugar or hemoglobin A1C data for the patient according to the clinical algorithm;

titrating a dosage amount and/or modifying a dosage frequency of the SGLT-2 inhibitor drug for the patient in response to processing the first set of medication log data for the SGLT-2 inhibitor drug for the patient and the first set of blood sugar or hemoglobin A1C data according to the clinical algorithm;

configuring, with the at least one server, a second generative voice prompt according to the conversational AI model, wherein the second generative voice prompt comprises a dosage instruction for the SGLT-2 inhibitor drug regimen for the patient,

wherein the dosage instruction comprises the titrated dosage amount and/or the modified dosage frequency for the SGLT-2 inhibitor drug according to the clinical algorithm; and

outputting, with the conversational agent, the second generative voice prompt to the patient; and

wherein the dosage instruction is provided by the second generative voice prompt, the dosage instruction comprises a dose of the SGLT-2 inhibitor drug to be administered to patient by the patient.